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Abstract
Background: Progress in clinical trials in infectious disease, autoimmunity, and cancer is stymied by a dearth of successful
whole cell biomarkers for peripheral blood lymphocytes (PBLs). Successful biomarkers could help to track drug effects at
early time points in clinical trials to prevent costly trial failures late in development. One major obstacle is the inaccuracy of
Ficoll density centrifugation, the decades-old method of separating PBLs from the abundant red blood cells (RBCs) of fresh
blood samples.
Methods and Findings: To replace the Ficoll method, we developed and studied a novel blood-based magnetic separation
method. The magnetic method strikingly surpassed Ficoll in viability, purity and yield of PBLs. To reduce labor, we
developed an automated platform and compared two magnet configurations for cell separations. These more accurate and
labor-saving magnet configurations allowed the lymphocytes to be tested in bioassays for rare antigen-specific T cells. The
automated method succeeded at identifying 79% of patients with the rare PBLs of interest as compared with Ficoll’s
uniform failure. We validated improved upfront blood processing and show accurate detection of rare antigen-specific
lymphocytes.
Conclusions: Improving, automating and standardizing lymphocyte detections from whole blood may facilitate
development of new cell-based biomarkers for human diseases. Improved upfront blood processes may lead to broad
improvements in monitoring early trial outcome measurements in human clinical trials.
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Introduction
The lack of biomarkers is one of the foremost obstacles to
advances in clinical medicine [1–3]. To our knowledge, there are
few accurate and highly sensitive blood-based biomarkers for
whole white blood cells, i.e., peripheral blood lymphocytes (PBLs).
PBLs refer to a broad class of white blood cells including T
lymphocytes (T cells), B lymphocytes (B cells), and monocytes.
Given that many PBL subtypes are exceedingly rare in blood
specimens (,1610
26), yet exert disproportionately large roles in
disease, biomarker innovation requires developing an accurate
method of separating PBLs from the very abundant red blood cells
(RBCs).
PBL separations and thus biomarker standardizations are
difficult to develop partly because of blood’s high viscosity and
its high ratio of red to white blood cells (700 RBCs to 1 PBL). In
our experience we have been unable to reliably obtain PBLs of a
specific subtype with the decades-old and labor-intensive method
of Ficoll density centrifugation for separating blood components.
With Ficoll, the PBLs and their subpopulations that we seek to
separate are lost in the separation process and the remaining cells
that are retrieved are poor in viability, purity, and yield. Accurate
methods of separating the many pathologic PBL subpopulations
are central to achieving advances in autoimmunity, infectious
disease, and cancer.
Although contributing to many diseases, pathological T and B
cells are known to cause autoimmune diseases of at least 50 types.
In our research on autoimmune type I diabetes, we seek to isolate
rare and cytotoxic T lymphocytes (T cells) that bear the cell
surface protein CD8. In type I diabetes, the sparse population of
pathological, autoreactive CD8 T cells are largely responsible for
destroying the insulin-secreting pancreatic islets of Langerhans.
These T cells account for only 0.6–2% of the total CD8 T cell
population. While some newer forms of centrifugation gradient
technology improve whole cell detection by 300-fold [4,5] they still
are not sensitive enough to detect the pathological CD8 T cells
whose amounts in human blood are orders of magnitude lower.
This same issue plagues others looking for rare antigen activated T
cells or pathogenic cells such as ongoing trials in AIDS, cancer,
infectious diseases and allergy. High clinical development costs
resulting in Phase III trial failures have become commonplace in
the AIDS and diabetes literature [6]. There may be a role in
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rare lymphocyte cell populations could be tracked early to show
the negative consequences of an ineffective drug or inadequate
dose of a vaccine.
Aiming to replace Ficoll gradient technology, we describe here
our novel method of isolating, automating and standardizing the
isolation of whole viable cells from fresh blood. Our method
incorporates magnetic technology to separate intact PBL subsets
from fresh blood samples without gradients and lysis buffers. We
provide data to determine quantitatively whether the magnetic
method is superior to Ficoll density gradients on three parameters:
viability, purity, and yield of PBLs. We also seek to demonstrate
that these three parameters are central for predicting success of
subsequent biomarker assays. Finally, we seek to demonstrate that
the magnetic method can succeed in isolating the extremely rare
subset of lymphocytes largely responsible for the pathological
attack against pancreatic islet cells [7]. This new method of PBL
separation could have far-ranging applications for biomarker
development not only for autoimmunity and vaccine development,
but also for diagnosis and treatment of any immune-related
disease, such as cancer, HIV, allergy and infectious diseases.
Methods
Subjects
Patients with Type I diabetes as well as non-diabetic control
subjects were recruited over a five-year period at the Massachu-
setts General Hospital. Patients and controls totaling over 500
subjects, were prescreened to ensure disease course and to exclude
subjects with potentially interfering medical conditions. All patient
and control blood was drawn into BD VacutainerTM tubes (BD,
Franklin Lakes, NJ) containing acid citrate and dextrose or EDTA.
Ethics Statement
The study was approved by the Massachusetts General Hospital
Institutional Review Board (IRB Protocol No. 2001P-001379).
Written consent was obtained from all blood donors.
Blood Preparation
For comparison of PBL separation methods, some PBLs were
prepared using Ficoll gradients. Ficoll Hypaque (Amersham
Biotech. Uppsala, Sweden) gradient centrifugation of fresh human
blood followed the manufacturer’s protocol. Remaining red blood
cells (RBCs) were removed by a 5-minute (on ice) incubation with
NH4Cl lysing solution (PharMLyse, BD, Franklin Lakes, NJ). PBLs
were evaluated for viability, yield and purity immediately after the
isolation.
For magnetic separations, direct isolation of human CD8 T cells
from fresh human blood were performed using large magnetic
beads (Life Technologies, Product No 113-33D), following the
manufactures protocol either by manual methods or with the new
automation methods described in this paper. Direct magnetic
separation methods were perfected to the extent that daily isolated
CD8 human T cells were obtained and studied from fresh human
blood less than one hour after the blood draw. A key feature of this
magnetic cell separation method is that the separated cells are free
of attached beads or antibody and therefore, the membranes of the
newly isolated pure cells were available for functional assays.
These cell separation methods were further standardized and
automated, using the Biomek FX robotic platform for achieving
improved uniformity of the cell preparations (Beckman Coulter
Fullerton, CA) as outlined below.
For the direct isolation of CD8 T cells from fresh blood,
antibody labeled with 3.5 mm diameter super-paramagnetic beads
(CD8 positive isolation kit (cat. #113.33D, Life Technologies,
Carlsbad, CA) were used. Before each experiment, the beads were
washed once with PBS buffer with 1% FBS to remove the sodium
azide stabilizing agent from the bead buffer. The beads were then
suspended in an equivalent volume of PBS buffer with 1% FBS
and placed into a 2 ml sample vial.
The volume of each subjects’ whole blood sample drawn was
recorded and used later for CD8 cell concentration determination.
Following a wash step, the blood samples were re-suspended to
15 ml volume with HBSS buffer in 50 ml (or 15 ml) conical tubes
and placed in a custom tube holder on the instrument for
processing and transfer to the 2 ml sample vials. Following
attachment and CD8 cell isolation, the beads were detached from
the cells using the detach-a-bead reagent supplied in the CD8
isolation kit. This reagent consists of a polyclonal antibody
directed against the antigen recognition site of the CD8 antibody
coated on the magnetic beads. This reagent detaches the
antibody/bead complex from the cells by means of competition
for the CD8 antibody binding site, essentially leaving a virgin cell.
The entire isolation process was performed on ice except for the
steps of removing the attached beads.
Flow cytometry
All lymphocyte cell isolations were analyzed by flow cytometry
using a FACSCalibur (BD Biosciences, San Jose, CA). Cell quality
was determined by quantifying cell viability, purity and yield. For
most flow cytometry studies, flow gates were set ‘‘open’’ for
inclusion of all cells. The open gate included cells of all sizes but
excluded cell debris, red blood cells, fragmented cells, and
apoptotic bodies. The open gate was chosen because cells
undergoing cell death, especially by apoptosis, can be detected
based on changes in light scattering properties and cell size.
Prior to flow analysis, sample volumes were recorded and a
small aliquot (10 mL) from each patient and control sample was
removed and the cells counted using a hemocytometer with a
microscope. Concomitantly, to help maintain viability, cells were
re-suspended in RPMI medium supplemented with 1% FCS and
antibiotics following a single 5 min wash by spinning, at ,600 g at
4uC. After the supernatant was carefully removed a fresh volume
of media was added to give ,1610
6 cells per ml, based on the
hemocytometer cell count and the original sample volume. Next, a
sample aliquot (50 mL) was transferred to a Falcon tube (BD
Biosciences) containing 100 mL PI stain solution (5 mg/ml).
Subsequently, FITC-CD8 antibody was added and after a 15
minute incubation in the dark and at room temp, the samples were
run on the flow cytometer.
We used propidium iodide (PI) to indicate dead cells, and FITC
conjugated to CD8 antibody for identifying CD8 T-cells. For these
studies, gates were set ‘open’ for inclusion of all cells.
Buffer reagents
For washing of whole blood, whether isolated with the Ficoll
methods or magnetic separation methods, we used 1x PBS or
HBSS, without calcium & magnesium chloride, supplemented
with 1 or 2% heat inactivated fetal calf serum (FCS) and 1%
antibiotics (penicillin/streptomycin and kanamycin Sulfate). For
washing the bead-cell complexes following their attachment to the
beads, we used Hanks Balanced Salt Solution (HBSS) supple-
mented with 1 or 2% heat inactivated fetal calf serum (FCS)
further supplemented with antibiotics as above. Following the
detachment of beads the CD8 T-cells are ready for final
suspension in RPMI-1640 media supplemented with 1–2% FCS
and 1% antibiotics and flow analysis.
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autoreactive T cells
For measurement of T-cell death, Propidium Iodide (PI)
(Oncogene, San Diego, CA) staining was used in combination





+) apoptosis or necrosis (AnnexinV
-PI
+). T-cell
subsets were identified using anti-CD3 antibody (CD4/8-T cells)
(Clone UEHT1; BD Pharmingen, San Diego, California). This
subset-specific antibody was linked to phycoerythrin (PE).
For the detection of the rare autoreactive T cells of type 1
diabetes, we used two methods. Autoreactive T cells for diverse
human diseases undergo accelerated apoptosis when exposed to
TNF unlike normal human T cells that show a small amount of
proliferation [7]. A 96 well plate based, WST-1 assay (Roche
Applied Science, Indianapolis, IN), was used to confirm cell death
versus viability. This is a cell proliferation assay that indirectly
measures cell death. The isolated CD8 T lymphocytes were plated
into 96 well U-bottom plate at a cell concentration of 100,000
cells/well. Cells were cultured overnight at 26uC in RPMI media
with 1% heat inactivated fetal calf serum. T cells were then treated
with TNF for 1 hr. After 1 hour of exposure to TNF, the WST-1
reagent (Roche Applied Science, Indianapolis, IN) was added
according to the manufacturers instructions. The cleavage of
WST-1, by metabolically active cells, was measured by a DTX
880 Spectrophotometer (Beckman Coulter, Fullerton, CA) at a
wavelength of 405 nm. Each experiment was performed in
triplicate. Test medium was used as background control. Data
were presented as a percent of proliferation compared to untreated
cells. Throughout this text we use the words pass and fail with
respect to this assay and this will mean that if killing is observed in
a diabetic sample it passes the test.
Detection of autoreactive CD8 T cells using Tetramers
CD8 T cells were isolated using magnetic bead separation from
fresh human blood within 1 hour of blood donation. For isolation
buffer we used Hank’s Buffered Salt Solution (HBSS, Invitrogen,
Grand Island, NY) without calcium and magnesium containing
2% heat-inactivated Fetal Bovine Serum (FBS, Hyclone, Logan,
UT) and dasatinib (100 nM, Axon Medchem, Groningen, The
Netherlands [8]). Isolated cells were stained with phycoerythrin-
labeled HLA-A2 Tetramers containing fragments of the islet
specific peptide IGRP (islet-specific glucose-6-phosphatase cata-
lytic subunit-related protein, sequence LNIDLLWSV). For
negative controls we used tetramers containing fragments of the
breast cancer peptide Her-2/neu (sequence KIFGSLAFL). The
IGRP tetramers were produced by the NIH Tetramer Core
Facility (Emory University, Atlanta, GA) whereas the Her-2/neu
tetramers were purchased from Beckman Coulter (Fullerton, CA).
Staining was in the dark for 30 min and the cells were co-stained
for FITC-CD8 (Beckman Coulter) during the last 10 minutes. The
cells were then washed in HBSS with 2% heat-inactivated FBS
and kept on ice until flow cytometry. A minimum of 25,000 CD8
T cells were analyzed on a Becton Dickinson FACSCalibur using
the CellQuest acquisition program. Separate samples of cells
labeled with FITC-CD8 and Propidium Iodine were analyzed to
determine purity and viability for each preparation. The results
were analyzed using either no gating, or gating on the main single
cell CD8 population, thus excluding debris, dead or apoptotic
cells, and clustered cells.
Robotic Hardware
All experiments were performed using the Biomek FX, a multi-
axis Liquid Handler platform (Beckman Coulter, Fullerton, CA) as
the platform for the development of the magnetic cell separation
process. The instrument we used was equipped with two robotic
pods. One was a 96-channel pod with a pair of grippers for
moving labware around the instrument work area (deck) in x, y
and z-motions. The second robot arm was a span-8 liquid handler.
This pod held a series of eight disposable probes (tips) that perform
liquid handling operations independent of each other. This arm
was used for pipetting, for sample aspirate/dispense operations, for
mixing, and when performing blood or reagent transfers. We used
1 ml volume tips (Biomek P1000s, Beckman Coulter, Fullerton,
CA) when using whole blood. This was the maximum allowable
for the instrument. We used 200 mL tips (AP96 P250’s (220 mL)
Beckman Coulter, Fullerton, CA) when transferring magnetic
beads to blood samples and/or detach-a-bead reagent to blood-
cell complexes. Pipetting operations such as aspirating and
dispensing of liquids was done at rates of ,200–300 mL/sec. We
also added a mechanical mixing option consisting of an Orbital
Shaker (Beckman Coulter, Fullerton, CA). This hardware piece
was mounted on the instrument deck and attached as an active
automated laboratory positioner (ALP) providing support, power
and computer control to allow selectable orbital motions at the
700–800 rpm rate of the shaker. Similarly, a 90 degree rotating
ALP was added to the deck in order to provide position orientation
control of the sample vial holder. The ability to adjust the sample
holder to the best position for span-8 tip access gave the robot arm
the best logistics for optimizing the hardware for high throughput.
Computer and Software
To control the instrument robotic operations, an x486 PC
computer was interfaced to the Biomek FX instrument. The
computer operates using the Windows XP Professional OS
(Microsoft, Redmond, WA). A large number of steps are required
to automate the magnetic bead-cell separation process, and many
of these steps had to supply liquid level position information
supplied as feedback to the software Method in order to keep red
blood cell contamination to a minimum during washing steps. We
learned through trial and error that the capacitive detection liquid
level sensing (LLS) technology supplied with the Biomek FX
instrument was unable to provide this accuracy on a consistent
basis when doing whole blood samples. This made it necessary for
us to write our own computer software program that could address
this problem.
Custom Software
We developed software in-house that successfully addressed the
above liquid level accuracy issue by utilizing geometry measure-
ments taken from our custom labware (see below). This information
was scripted so that the code could calculate real-time tip positions.
This was possible by incorporating a system feature of internal
tracking and summing of the number of z-axis stepper motion steps
needed. This information was used by the program to calculate
precise tip position information. The resulting Method (about 500
lines of code) contained various pre-built software components from
both Microsoft OS and the Beckman Coulter Biomek software. We
used the Microsoft Visual Studio 6.0 suite of tools (Microsoft,
Redmond, WA). The source code is available in the Supporting
Information section (Document S1).
The above code was written so it would be transparent by
providing an interactive interface module that allowed the user a
way to navigate, specify and select the experimental variables used
to complete automated cell separation process. All variables are
specified by the user at the beginning of the experiment and read in
by the software and translated by the Method into specific machine
instructions to be completed under control of the computer. This
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equivalent of what manually would be done at the ‘‘bench’’ when
performing the magnetic bead-cell isolation process. This software
interface simplifies user interaction with the robot allowing for walk-
away operation with automatic alerts, if desired, to the user if there
is any cell issue while doing an isolation.
Sample Dilutions
The large number of red blood cells in whole blood required a
sufficient number of washes to achieve a dilution factor of .10
12.
Getting a wash reagent capacity with proper reservoir orientation
on the deck for robot access was critical. We used a 40 ml/well by
six well reservoir (# 534680 (Beckman Coulter, Fullerton, CA)
oriented at a 90 degree placement to allow all span-8 tips equal
access. To meet this condition, a custom reservoir mounting
support was designed and built to the specifications positioning the
reservoir by 90 degrees on a 3 by 1 ALP. This gives the span-8 tips
equal access to all reservoir wells simultaneously to speed-up wash
steps and minimize potential tip cross-talk occurring when
separating different samples.
Sample vial holder
Keeping with the 96-well micro-titer plate format of the FX
instrument, but needing larger ml sample volumes of blood when
isolating rare lymphocyte cell subsets, we designed, built and tested
a custom sample vial holder (Document S2). Unlike the 96-well
plate which has many small fixed wells in a standard footprint, we
kept the footprint but redesigned the plate body to enable us to use
removable 2 ml sample vials (Corning Inc. # 430661 round
bottom cryogenic Nunc vials, Corning Inc, Corning, NY). The
2 ml vials are placed into the custom holder which now has a 4-
row by 6-column format. One row of 2 ml (sample) vials
constitutes one blood sample and contains a total of 12 ml. There
are 2462 ml potential removable vials (wells) and a possible four
blood samples per custom sample holder. The holder was made
from white polypropylene plastic set to standard titer plate
footprint dimensions. The 2 ml removable sample vials are
designed to be discarded at the end of each experiment and the
sample vial holder reused.
The sample vial holder was designed to be compatible with a
custom magnet plate positioned and underneath the vial holder to
allow small magnets to capture the magnetic beads or bead-cell
complexes. The sample vial holder design included machined slots
to accommodate pick-up and movement of the holder by the span-
8 gripper on the instrument deck.
Ring magnet(s) and magnet base plate
Neodymium iron boron (NdFeB) rare earth ring magnets (7500
OD x .50 ID x 5 mm), grade N50 (K&J Magnetics, Inc., Jamison,
PA) were used to separate the cells of interest from whole blood on
the Biomek FX instrument. The symmetrical ring magnet
geometry and their several thousand Gauss field strength each
make them ideal candidates to use for magnetic bead separation
applications as they quickly and easily separate such beads present
in 2 ml vials of whole blood.
The two piece custom magnet plate design used to hold the ring
magnets in place consists of a magnet support matrix to place each
magnet made from aluminum stock, and a base piece made from
aluminum alloy with high permeability for magnetic fields
(Document S2). This combination minimizes field interference
by magnetic field lines under the sample vials. The magnet base
assembly is capable of supporting twenty-four rare earth ring
magnets, one for each sample vial. In operation, the robot moves
the sample vial holder to location over the ring magnets and
lowers the sample vial holder onto the magnet base plate bringing
the sample vials into the ring magnet center(s).
To help maintain uniform field patterns for the sample vials or
positions, the magnet base plate remains populated with the full
complement of 24-magnets. These ring magnets can remain in
position in the plate, even if using fewer than the four possible
samples in the sample vial. Additionally, to help keep external
magnet fields in check, each ring magnet is placed into the magnet
support holder using an alternating north-south pole facing
configuration.
When in position, the magnetic field pulls the magnetically
tagged cells in the sample vial(s) into a continuous ring around the
lower inside of each vial. This allows pipetting of liquid by the
span-8 without disturbing the tagged cells. The ring position is low
enough in the vial bottom to allow use of both small 200 mL and
larger ml volume washes.
Two stage magnet post rack
Initial magnetic bead and cell separation experiments began
with a two stage magnet post (tube) rack (Beckman Coulter,
Fullerton, CA). This magnet tube holder combination consists of a
15 magnetic position holder arranged on a standard plate
footprint. The 15 cylindrical (post) magnets are made to be
inserted into matching positions on the underside of the top-piece
custom MagTubeRack holder. The top labware piece contains
2462 ml vial positions arranged as 4-rows by 6-columns), of 2 ml
tubes (Corning, Corning Inc, Corning, NY). Unlike the ring
magnet configuration, each sample vial for the two stage post
magnet sits adjacent to one or more post magnets, and thus
experiences magnetic interference. This design uses the same
number and kind of sample vials used for the custom ring magnet
sample vial plate.
Sample Delivery with Blood Tube Holder
Because blood is drawn in standard 10 ml BD Vacutainer tubes
(BD, Franklin Lakes, NJ), dispensing these volumes for delivery by
the robot on the instrument using 2 ml vials requires some means
to properly allocate the sample(s). To automate the process the
span-8 robot arm needs to gain access to the original starting
volume of whole blood so it can transfer the sample onto the deck
and into the 2 ml sample vials. We accomplished this by designing
and building a custom tube holder for standard sterile Nunc vials.
This holder was ALP mountable on the instrument deck and
accessible by the span-8 so it could do liquid transfer operations
into the 2 ml sample vials. The tube holder was designed to use
50 ml or 15 ml conical tubes (Falcon tubes, Becton Dickinson,
Franklin Lakes, NJ). The blood is placed into the conical tubes
following washing (under a laminar hood to maintain sterility) and
loaded into either 50 ml or 15 ml conical tubes. These are placed
into the custom holders on the robotic platform on the instrument
deck then automatically transferred into 2 ml sample.
Results
With the goal of developing viable whole cell PBL biomarkers,
we first sought to create a cell separation method superior to Ficoll
density gradients: we developed and tested a new method of
magnetic separation. We also sought to ensure that the new
method was accurate and sensitive enough to detect PBL subtypes
of special interest to our laboratory. Once we developed the
manual version of this new method, we sought to automate it by
developing liquid handling software and hardware with a
distinctive type of magnet configuration to isolate the cells of
interest. We also performed bioassays to determine whether the
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pathological (autoreactive) subset of CD8 T cells, which are largely
responsible for autoimmune attack in type 1 diabetes. These final
experiments were undertaken to demonstrate that magnetic
methods of blood cell separation that accurately detect and
quantify PBLs and subpopulations of interest can lead to new
standard biomarkers using viable whole cells.
Comparison of Manual Ficoll Gradient Separation vs.
Manual Magnetic Separation
We first compared the accuracy of blood separations by Ficoll
density gradient versus the new magnetic method. Three
parameters were studied: cell viability, purity, and yield, each of
which was quantified by flow cytometry. We also examined the
cellular composition of the isolate, another measure of purity
(Fig. 1). Each line in Figure 1a and Figure 1c represents one
healthy subject’s blood sample studied on a single day.
With the Ficoll method (N=35 subjects), the viability of PBLs in
each individual sample ranged from 40 to 60% viable of the
isolated lymphocytes (Fig. 1A), as determined by counting cells
stained with propidium iodide (PI), which stains only dead cells.
This finding indicates that up to a maximum of 60% of cells in the
isolate were already dead immediately after harvest from the fresh
blood. As shown by flow cytometry studies on single isolated blood
Figure 1. Comparison of accuracy of isolation. In recruited subjects, the accuracy of PBLs or lymphocyte subset (CD8 lymphocytes) isolations
from fresh blood was compared between the Ficoll method (N.35 subjects) (A,B) and the manual magnetic method (N.335 subjects) (C,D).
Accuracy of the isolates was analyzed by viability (A,C), purity (A,C), yield (A,C), and cellular composition by analysis of FSC (forward)/SSC (side) scatter
(B,D) from flow cytometry. The Ficoll method (A) was inferior to the magnetic method on viability and purity (C). The magnetic method (C) also
generated higher yields but the variability was high, reflecting inherent variability found across healthy subjects. In addition, the cellular composition,
as determined by scatter plots (B,D), revealed that the magnetic method isolated the cells of interest, CD8 T cells, whereas Ficoll produced a mix of
PBLs sufficiently contaminated with dead cells and mononuclear cells that it would require further purification to detect autoreactive CD8 T cells.
doi:10.1371/journal.pone.0022430.g001
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PBLs, and, worse yet, the dead cells became a potential interfering
source of background noise by flow cytometry (Fig. 1B).
Purity (Fig. 1A) was measured by the percentage of CD8 T cells
within isolates of PBLs. Due to the lack of cell specificity, purity
using Ficoll only reached a high of 20% in normal samples. Purity
was further analyzed by the cellular composition of the isolated
PBLs by a scatter plot of Forward Scatter (FSC) and Side Scatter
(SSC) (Fig. 1B). The cellular constituents were primarily
mononuclear cells, dead cells, and lymphocytes, the latter of
which consisted of a mix of CD4 and CD8 T lymphocytes and B
lymphocytes. The yield, or the total number of whole PBLs per
1 mL of human blood assayed by flow cytometry (Fig. 1A), was a
mean 0.04560.003 (SEM) 610
6 (n=35). With the magnetic
method that eliminated the need for gradients such as Ficoll for
blood separations and without any use of a lysis buffer (Fig. 1C, D),
the findings were robust. The presented Ficoll data had
demonstrated CD8 cells at low levels of purity (Fig. 1A). Using
the new magnetic methods applied to fresh blood, we found
striking improvements over Ficoll for all three parameters (Fig. 1C,
D). The viability of CD8 T cells was very high and averaged
98.260.3% (n=335). The mean purity of CD8 cells obtained by
flow cytometry was 90.860.5 (n=334). The purity of the sample
was bolstered and self evident by the analysis of the scatter plot
(Fig. 1D). The plot of FSC vs. SSC showed an abundance of intact,
normal CD8 T cells, negligible percentages of dead cells, and
absence of monocytes. The yield, or the total number of whole
CD8 cells per 1 mL of human blood, was 0.2360.01610
6
(n=326), a value more than five-fold greater than the yield with
Ficoll.
Development and design of automated magnetic
lymphocyte separations for fresh human blood
The goal of this project was to demonstrate the accuracy of
magnetic separation methods in terms of viability, purity and yield
of cells. It was our belief that these manual methods should be
automated for finer degrees of accuracy and reproducibility for
clinically useful whole cell biomarkers. If successful, the automa-
tion process would also increase capacity, accuracy and set the
stage for another level of standardizations that would remove the
human factor from manually performing the blood separation
process. At this time point we were working under the assumption
that the standardization of whole blood separations, by the defined
parameter of whole cell viability, purity and yield, would also
strengthen the accuracy of downstream whole cell biomarker assay
perfection.
One of the early decisions in the design of the whole blood cell
separation process was to find a paramagnetically tagged antibody
reagent that was compatible with robotic whole blood separations
and could bind PBLs of interest, for instance CD8 lymphocytes.
After comparing a variety of paramagnetically linked antibody
methods, we found that antibodies labeled with 3.5 mm diameter
super-paramagnetic beads resulted in lymphocyte subpopulations
with the best purity, yield and viability. This is a relatively large
bead size for the paramagnetic antibody reagent but it was chosen
because larger beads expedite cell migration to the side of the tube.
Also, large magnetic beads attached to the blood cells of interest
were likely to eliminate the problems inherent in the use of their
small counterparts. Small paramagnetic particles attached to
antibodies require other blood processing steps such as centrifu-
gation, long time periods for cell separations through viscous blood
and complex wash and handling steps due to the longer times to
bring a cell to the side of the tube. Also, larger magnetic forces
would need to be applied to smaller particles. In addition it was
generally observed that large magnetically linked antibodies
require the binding of fewer cell surface epitopes to facilitate cell
movements to the side of the tube.
Using this large bead size for the paramagnetic system, we built
a robotic workbench configured as a platform to integrate
hardware and software for automating lymphocyte isolations from
fresh blood specimens. Combining paramagnetic bead technology
combined with the design of external magnets, we tested and built
the platform for its ability to separate whole cell lymphocytes,
typically CD8 lymphocytes. The purpose and goal of the robotic
system was to build a platform that did not require centrifugation
steps that are difficult to automate and also to avoid any whole
blood lysis steps requiring reagents that might facilitate removal of
contaminating RBCs, but would also decreased the viability and
yields of the lymphocytes. The workbench liquid handling and
robot motions were controlled using custom software to specify
position, movement, and mixing of blood samples held by lab ware
built to function within the designated instrument deck area. We
worked within the robotic platform constraints to engineer, build
and test different magnet geometries, magnet holders, and
mounting plate assemblies made to support sample plates typically
holding 2.0 ml sterile cryo vials also known commonly as Nunc
vials. We then took the best working magnet configurations (Fig. 2),
sample tube plate designs and liquid processing requirements to
seamlessly integrate each hardware piece with the automation
movements (See Methods and Document S2).
Figure 2 shows the two most promising of several designs for the
platform sample holders. Depicted on the left side is an automated
robotic platform based on cylindrical (post-shaped) magnets,
whereas the right side of the figure shows a design based on ring
shaped external magnets that apply forces to the antibody linked
cells with magnetic bead particles. FSC/SSC flow cytometry
showed that the ring magnet design produced the purest cells of
interest, in this case a subpopulation of white blood cells
lymphocytes, called CD8 T cells. Impurities in the yielded cells
with post-shaped magnets presumably were due to interference
among the magnetic fields of adjacent cylindrical magnets. This
was avoided by using ring magnets embedded in a flat plate where
interfering fields between magnets were not an issue and overall
capacity increase was possible by placing the magnets and Nunc
tubes closer together.
Isolation of rare blood cell populations by magnetic
separation: impact on biomarker assays
Taken together, the findings from .335 fresh blood samples
studied by the magnetic method (Fig. 1C), combined with the
ability to automate this blood separation process with robotic
platforms (Fig. 2B), were convincing enough to justify the
examination of these separated cell preparations in biomarker
assays. We were particularly interested in testing the isolated whole
blood cells for the reproducible detection of rare CD8 T cell
subsets (approximately 0.6–2% of the total cell population) that are
the autoreactive T cells in type I diabetes. As Figure 3A depicts, we
hypothesized that with whole blood derived cell preparations
featuring high viability, purity, yield and only infrequent RBC
contamination, it was timely to see if the rare cells of auto-
immunity persisted and were detectable. For this initial biomarker
testing, autoreactive T cells were first studied by an indirect
method of exposing isolated CD8 T cells to Tumor Necrosis
Factor (TNF), which selectively kills autoreactive, but not normal
CD8 T cells, which continue to proliferate [7]. After TNF
challenge, the remaining CD8 T cell isolate was assessed for
autoreactive cells by the WST assay for T cell proliferation. The
second biomarker method we used to assess the impact of the
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was the more highly sensitive ‘‘tetramer’’ method. This highly
sensitive method of autoreactive T cell detection directly evaluates
cells for the presence of rare autoreactive CD8 T cells, and
involves the incubation of whole blood isolates with self peptide
bound with fluorescent HLA class I protein. Only a single clone of
autoreactive T cells should recognize the tetramers in flow
cytometric studies.
We performed a functional biomarker assay examining blood
samples from 56 pairs of type I diabetics and matched non-
diabetic controls to determine whether the automated magnetic
method was sensitive enough to detect the presence of rare cells of
interest, namely CD8 T cells (Fig. 3A,B). Using a relatively
insensitive assay for autoreactive T cells, we found that 79%
(n=44/56) of diabetic blood samples isolated by the automated
magnetic method were correctly identified as having the rare
autoreactive cell type, i.e., the ‘‘pass group’’. In marked contrast,
none of the samples from the same 56 diabetic patients tested by
Ficoll was found positive, i.e., the ‘‘fail group’’. In other words, the
prevailing method of Ficoll separation had a 100% failure rate.
A ‘‘pass’’ rate of 79% with the WST assay after the magnetic
method is excellent compared to the Ficoll method with 0%
Figure 2. Automated magnetic separations of lymphocytes from human blood using a robotic platform. We compared two different
plate designs for the robotic platform (A,B). For each test system, Nunc vials were loaded with fresh human blood and paramagnetic beads tagged
with the antibody to the whole blood cells of interest was added to the sterile vials. This blood and antibody mixture typically was tested for its ability
to separate lymphocyte subsets, such as CD8 or CD4 white blood cells. The most robust platform design gradually culminated in two different plate
designs with varying configurations of the external magnets. On the left (A) is a plate design with a post magnet on the outside of the Nunc vial. On
the right (B) is a plate design with a ring magnet design at the base of the Nunc vial. The resulting separated lymphocytes were evaluated for the
highest yield, viability and purity. It was first thought that a full-length magnet along the side of the tube would facilitate the cellular separations.
However, the disadvantage of this plate design was that every magnet experienced interference from the surrounding magnets, thus decreasing the
overall density of Nunc vials for maximal efficiency and/or decreasing the magnetic force. As a result, this method produced lymphocyte preparations
contaminated with RBCs and magnetic debris, as shown in the left scatter plot of the yielded cells. In contrast, the ring magnets in (B) produced
internally consistent magnetic fields that did not interfere with adjacent ring magnets since the pulling force was exclusively directed to the interior
of the vial. Also, the ring magnet configuration maximizes the plate capacity for the maximal number of Nunc vials per plate, and allowed the
isolation of CD8 lymphocytes from whole blood with much higher purity (right scatter plot).
doi:10.1371/journal.pone.0022430.g002
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critical that the separation method yields healthy cells of sufficiently high purity. (A) Schematic depiction of magnetic and gradient methods. The
magnetic method is gentle, highly selective and retains the lymphocytes of interest (blue cells), whereas the gradient method has remaining red
blood cells (red dots) and low viability (dark cells), while the cells of interest are largely lost due to cell death. (B) Comparison of performance
parameters of magnetic and Ficoll gradient separation methods. Autoreactive CD8 T cells were isolated from 56 blood samples from human type I
diabetics with both Ficoll and magnetic methods. Using the insensitive WST biomarker assay of rare autoreactive T cells, only magnetically separated
cells showed the presence of the cells (Pass); Ficoll isolated cells uniformly lacked autoreactive T cells. The accuracy of the cell separation method was
established by determining viability, purity, and yield. The results show that extremely efficient cell isolation procedures with high yield and high
viabilities are required to preserve the cells of interest. (C) Flow cytometry with tetramers specific for autoreactive CD8 T cells shows that these cells
are present and detectable after separation from patient blood samples using our magnetic method.
doi:10.1371/journal.pone.0022430.g003
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whether all improved methods of cell separations are adequate for
this relatively insensitive biomarker assay. We therefore more
finely studied the whole cell isolates to see if subtle differences in
the cell isolation methods, as quantified by viability, purity and
yield, might impact the rare cell detection with the WST assay.
This was important from a clinical trial viewpoint, since if some
parameters of monitoring autoreactive blood cell separations could
have quality control cut offs, inadequate quality preparations of
cells would not be studied further in biomarker assays. Therefore,
we conducted an analysis (Fig. 3C) of only the magnet samples that
passed (the 79% of patients with true positives) to determine which
of the blood separation parameters—viability, yield, or purity—
was most determinative for enhancing the pass rate as compared
to the 21% of the magnetically separated cells that failed. The
results show that better yield and viability are more important than
is purity for detecting this rare cell population of autoreactive CD8
T cells. Figure 3C shows that a slight reduction in viability from
97.960.2% to 97.360.2% (average 6 SEM; p=0.04) makes the
difference between passing or failing detection by the WST assay.
We infer from this finding that the difference is minor because the
population of apoptosis-prone, autoreactive CD8 T cells only
accounts for a small segment (0.6%) of the total CD8 T cell
population. Thus, these cells can be induced to die very easily.
Therefore, the isolation process must be extremely gentle and
efficient otherwise these cells will no longer be present in the final
isolate.
We also observed a statistically significant difference between
yield in the ‘‘pass’’ versus ‘‘fail’’ group (Fig. 3C, 444,700644,900
versus 340,800628,000 CD8 T cells per mL of donor blood;
p=0.03). This was expected because viability and yield are
correlated in this type of process. Finally, there also was a trend for
higher purity as being important to detection of autoreactive CD8
T cells, but the difference was not significant and would require a
much larger sample size to reach sufficient power (Fig. 3C;
99.260.29% versus 98.860.35%; p=0.20). The slight difference
between passing and failing detection is approximately 0.5% in
this relatively insensitive assay for autoreactive CD8 T cells. The
analysis showed that even the magnetic method of blood
separations could be impacted by cell quality and, at least for
these samples, perfection of viability, yield, and purity avoided
false negatives. Minor quantifiable differences distinguish between
detection or non-detection of this rare autoreactive cell population.
Put another way, blood separation methods impacted rare T cell
detection through biomarkers.
The detection of rare autoreactive T cells isolated from blood
could also be impacted by the choice of biomarker assay since
different assays can have different degrees of sensitivity. The
second biomarker method applied to assess the impact of
improved isolation method on the detection of lymphocyte
subpopulations was the more sensitive ‘‘tetramer’’ method. This
highly sensitive method of autoreactive T cell detection involves
the incubation of whole blood cell isolates with self peptide bound
with fluorescent HLA class I protein. Only a single clone of
autoreactive T cells is recognized, i.e. the rare pathogenic T cells.
The published literature had previously reported using Ficoll
methods that rare autoreactive T cells could not be found in long
term diabetics with Ficoll isolation methods and ‘‘tetramer’’
methods [6]. Using patients who had ‘‘failed’’ in the insensitive
WST assay but had separated lymphocytes from magnetic
methods, i.e. part of the 21% fail group, we uniformly detected
peptide specific autoreactive T cells with the more sensitive
‘‘tetramer’’ assay (Fig. 3D). Thus, refined and automated blood
separations using magnetic methods led to successful rare T cell
detections. The quality of cell preparations and the sensitivity of
the biomarker assay in combination were synergistic in success.
Automation leads to reduced labor and process costs
In addition to the inaccuracies inherent in the Ficoll isolation
methods, the labor cost of the resource-intensive Ficoll separation
of blood specimens is also rate-limiting for the development of
whole cell lymphocyte isolations. To assess economic impact, we
compared the labor time needed for manual PBL cell isolation
using the new magnetic methods against the automation
methodology described in this paper. We estimated resource
needs and an overall estimate of gain in productivity. As is shown
in Figure 4, the savings in manpower by automating cell isolations
by the magnetic method are significant and will translate in
Figure 4. Comparison of labor hours needed to perform manual versus automated CD8 cell separation in our laboratory. Based on
our workflow, one research associate works 4.5 hours to process blood samples from one diabetic patient and one control; or a total of 18 hrs for 8
patients. In our current automated setup one associate can initiate the processing of 8 samples in parallel and finish in 3 hrs while being able to
perform other activities once setup is completed. Such dramatic savings in amount of direct labor will translate in large cost savings and increased
throughput.
doi:10.1371/journal.pone.0022430.g004
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top of improved sample quality and consistency of meaningful
data.
Discussion
Escalating clinical care costs and high translational costs for new
drug development are a motivation to develop better biomarkers
for human disease. Biomarkers are important tools for clinical
development since they provide early signs of drug efficacy,
toxicity, dosing and failure. Indeed, much progress has been made
in the development of biomarkers based on pharmacogenomics,
mRNA and proteomics to track the human response to new drugs
in clinical trials. What is lacking in biomarker development is the
routine use of human blood whole blood cell markers of disease.
The examination of lymphocytes and of the rare antigen-specific
lymphocyte subsets is relevant to vaccine and AIDS research, as
well as to infectious disease, autoimmunity and cancer trials. A
remarkable number of opinion papers estimate that biomarkers on
patient populations could lead to cost savings of $80 billion per
year in streamlining clinical trials, yet one important facet of
biomarker development, viable whole white blood markers, is
conspicuously absent [7].
The use of Ficoll for the separation of blood into PBLs and
RBCs was introduced in 1968 [9]. Since then it has become the
mainstay for the separation of white blood cells and remains the
method of choice in many clinical laboratories. Even so, Ficoll
gradient separations result in poor quality PBLs combined with
low yields and poor viability.
The literature shows that there are potential problems with
Ficoll separations, such as contamination with iodine [10], loss or
death of specific subpopulations of lymphocytes [11,12] and
changes in expression of adhesion molecules [13]. Also the use of
Ficoll has failed to lead to any standardized biomarkers from
whole blood nor did it lead to the easy standardization of
biomarkers in clinical trials that depend on viable lymphocytes.
In this project we hypothesized that the poor or missing
biomarkers based on whole blood lymphocyte preparations is
likely due to inadequacies in the upfront process of whole blood
cell separations. We reasoned that the decades old methods of
whole blood cell separations were perhaps losing the cells of
interest or the cells of interest were dying due to the harsh isolation
conditions (Fig. 3A). Recent world-wide technology to isolate
subpopulations of blood cells has been developed and these
methods now frequently utilize paramagnetic particles coated with
antibodies against specific cell surface markers to separate the
white blood cells of interest. In addition, it is important to note that
the methods as presented and further developed here can be
performed on whole blood without the need to lyse the red blood
cells nor enrich the lymphocytes using pre-processing steps that
often involve gradient centrifugations. Our need for improved
blood cell isolation methods has led us to the development of the
automated magnetic separation methods that are the subject of
this paper (Fig. 2).
In general, the isolation of white blood cells from whole blood is
difficult and biologically hampered by the fact that the blood
contains red blood cells that exceed the number of white blood
cells by more than 700 to 1. Separations are further hindered by
the viscosity of whole blood, the presence of serum proteins and
the large number of cells per ml of blood. Many protocols
therefore call for the pre-enrichment of WBCs by means of
gradient separations and/or RBC lysis, prior to the application of
magnetic bead separation. For rare cell populations this defeats the
advantage of using magnetic bead technology as many cells
already have been lost or damaged after this pre-enrichment step.
This is demonstrated by the low yield after Ficoll gradient
separations (compare Figs 1 and 3). For rare cell populations, it is
critical that these cells are preserved by the isolation process and
remain healthy for subsequent biomarker assays. Based on these
considerations we decided to concentrate our efforts on cell
separations directly from whole blood without previous lysis or
gradient steps.
As a demonstration of the need for the highest possible quality
of isolated blood cells to standardize biomarkers from blood, we
present data that demonstrate that preparations of whole blood
lymphocytes from fresh blood can lead to biomarker success, in
contrast to Ficoll blood isolations that result in uniform failures.
We show that a WST-1 assay for rare autoimmune cell detection
only works reliably when the isolated blood cells are of sufficiently
high yield, viability and purity (Fig. 4). The relatively small
difference in viability, yield and (to a lesser extent) purity between
the ‘‘pass’’ and ‘‘fail’’ groups is presumably due to the fact that
these cells only constitute a very small fraction (less than 1%) of the
total CD8 T cell population. Since these cells are more apoptosis-
prone, they will be under-represented, or missing altogether, in the
batch of isolated cells unless the blood separation process is
efficient. In further support of the hypothesis that lymphocyte
preparations from whole blood can lead to biomarker detection,
we observe that automation of blood separations can also be
successful.
The processes required to separate blood cells are tedious and
time-consuming, especially for Ficoll methods. It usually takes a
trained lab worker several hours to generate the necessary
isolated cells. In addition, even when performed by the same
skilled individual, there are quality and repeatability issues
associated with the isolated samples that tend to make it hard
to control uniformity and consistency. Variation can be
significant; it tends to increase when more than a few samples
are run in parallel and tends to be exacerbated due to person-to-
person variability. When there is a need to scale-up, as would be
the case in the clinic, the need to have greater capacity and/or
higher throughput must be addressed. Consistent sample quality,
the importance of timing and being able to process samples at all
hours makes scheduling complicated. Many of these issues can be
avoided by automation of the cell isolation process. The time-
savings with the automated method will translate to large cost-
savings, especially in a clinical setting, where high throughput is
important.
Improving the efficiency of the blood separation process for the
implementation of biomarkers represents a major advance in basic
science with near-immediate translation to the clinic. The use of
biomarkers to identify and test drug candidates may allow an
increase in the numbers of new drugs and hopefully new drug
approvals and is a current research topic of great interest for
speeding the drug approval process with cost efficiencies [14–16].
In this paper, we show the impact of changing the basic concept of
how fresh human whole blood is handled to obtain viability
lymphocytes for biomarker studies. We eliminate both gradient
and lysis methods to enrich lymphocytes and showed that the
entire process can be automated with magnetic methods of blood
cell separations. These innovations not only resulted in marked
improvements in the yield, viability and purity of the cells, but also
led to the validation of biomarkers assays that have previously
failed in human populations. Biomarker data can be extremely
valuable as predictors of drug effects. Our data suggests that the
automation of whole lymphocyte separation from fresh blood may
be central to developing PBL biomarkers aimed at fulfilling the
needs of clinical research and translation to the clinic.
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Document S1 Blood cell isolation source code for
Biomek FX. To automate the isolation of human CD8 cells
from whole blood we developed source code for the Beckman
Coulter Biomek FX robotic platform. A user interface was written
using Microsoft scripting software and Biomek liquid handler
software templates to create a Method that was optimized for
control of all CD8 isolation steps. This script uses software palettes
and project file information to configure all the mechanical actions
and functions of the instrument’s robotic motions and to
accurately process those instructions as part of the hardware setup
and control.
(PDF)
Document S2 Custom sample tube holders. We custom
designed and built sample holders for 2 ml sample vials (up to 24
vials) and a maximum of four patient samples (one for each row).
A sample occupies one-row of the four-row (by 6 column) holder
design. Each (sample) row holds six vials to provide sufficient
volume (up to 12 ml) to provide a sufficient number of cells of
interest to be collected. Shown are several different views…clock-
wise from top left, are tube holder top view, viewing the tube
holder at an angle, and a side view of both the sample plate with
two (of 24) vials sitting within the holder and on the magnetic
separation plate. The exploded view shows the various engineering
components used to fabricate the sample holder base and
magnetic separation plate. This plate is used to pull any magnetic
beads that are present in the sample vial solutions to the sidewall.
The plate design includes the use of 24 separate (rare earth) ring
magnets (one ring magnet for each sample). One (2 ml) sample vial
is illustrated above the sample holder. The use of multiple plate
layers ensures correct ring magnet placement to allow for accurate
sample vial x, y, z insertion position. The various cut-away plates
also help to confine (isolate) magnetic field lines to minimize
unwanted interferences and field line overflow at the bottom of the
sample vials. Separately, a sample plate holder is shown (top-right)
with inserted sample vial. The slot seen near the top (matching on
opposite side) is used by the robotic arm to move the plate on/off
the magnet plate. On the bottom right is a cut-away side view of a
sample holder sitting on a magnet separation plate with the sample
vial positioned in the ring magnet of an assembled magnet
separation plate. As shown, the ring magnet is positioned near the
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